China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Factors influencing the response to symptoms among family members of acute ischemic str... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase I Study of INNA 1605 Ointment in Healthy Adults'. The following are the other rel... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Preliminary exploratory clinical study on efficacy, safety and radiation dosimetry of^1... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and safety comparison of endoscopic ultrasound-guided lauromacrogol ablation v... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Study on the Role of Omalizumab in Children with Severe Allergic Reactions'. The follow... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'The 95% Effective Dose of Tegileridine for Suppressing Tracheal Intubation Response in ... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Research on Intelligent Recognition and Diagnosis of Burn Wound Images Based on Deep Le... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Correlation Between Peripheral Blood Cold-Inducible RNA-Binding Protein Levels and the ... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical Study of ULDR for Autism Spectrum Disorder'. The following are the other relev... Read More
China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, open-label, multi-cohort, phase II clinical study of vibecotuotamab comb... Read More